Investors Can Take the Lead in a Class Action Against Capricor Therapeutics, Inc. for Securities Fraud

Investors Alert: Leading the Class Action Against Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently embroiled in a significant class action lawsuit, a situation that provides an essential opportunity for investors. The litigation stems from serious allegations of securities fraud, implicating the company in misleading communications that have significantly impacted share values. Schall, Brown & Schwartz LLP (SBS), a prominent firm specializing in shareholder rights litigation, is spearheading this case, and they invite affected investors to engage in this critical legal pursuit.

Background on Capricor Therapeutics

Capricor is a clinical-stage biotechnology company that focuses on advancing innovative therapies. However, during the class period from December 17, 2025, to July 26, 2026, the company's operational decisions came under scrutiny. Allegations suggest that Capricor made false and misleading statements regarding crucial clinical trial data pertaining to Deramiocel, their leading therapeutic candidate.

Specifically, the lawsuit claims that the firm altered the statistical analysis plan related to clinical data without FDA agreement. This reversal raised significant concerns about the likelihood that the FDA would approve Capricor's Biologics License Application (BLA) for Deramiocel, thereby putting investor interests at grave risk. The lawsuit asserts that Capricor's public statements during this period were misleading, leading to considerable financial damage for investors once the reality of the situation surfaced.

Legal Framework and Class Action Details

The case revolves around violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 established by the U.S. Securities and Exchange Commission. The complaints, as highlighted by SBS, suggest a pattern of misrepresentation by Capricor that left many investors vulnerable to the consequences of inaccurate market information. Investors who purchased shares of Capricor during the defined class period are encouraged to reach out to Schall, Brown & Schwartz for potential lead plaintiff roles. Notably, participation as a lead plaintiff is not a prerequisite for recovery in the case.

Critical Dates to Remember

- Class Period: December 17, 2025 – July 26, 2026
- Deadline for Filing Claims: September 28, 2026

Call to Action for Investors

Investors who suffered losses due to Capricor's alleged fraudulent behavior are urged to act swiftly. Engaging with the class action lawsuit not only represents an opportunity for individuals to recover their investment losses but also serves as a collective stand against corporate misconduct. Shareholders can reach out to Brian Schall or David Schwartz of SBS for a free consultation regarding their rights and participation in the class action.

Why Choose Schall, Brown & Schwartz?

SBS has a proven track record of advocating for investors on a national scale. With a team of experienced attorneys, including founding partners Brian Schall, Andrew Brown, and David Schwartz, the firm is well-equipped to navigate the complexities of securities litigation. Their commitment to protecting shareholder rights and fighting for equitable outcomes is evident in their work. By presenting this case, SBS aims to hold Capricor accountable for any misleading practices that may have adversely affected its shareholders.

To learn more about the class action, or if you believe you qualify as an affected investor, don’t hesitate to reach out to SBS. You can visit their website or contact them directly by phone or email for more details on how to join the case and advocate for justice.

In conclusion, the opportunity for investors to lead in this class action against Capricor Therapeutics is not only crucial for potential recovery but also monumental in upholding accountability within the biotech sector.